APAC The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well as highlights from Indonesia, the Philippines, and Malaysia Singapore medicines regulator world’s first to achieve highest maturity level in…
Asia-Pacific Stewart Campbell, Vice President and General Manager, Asia Pacific, West Pharmaceutical Services, highlights how the drug containment and delivery system industry is evolving to meet the rapidly changing needs of Asian biopharma; West’s crucial role in the fight against COVID-19 and how it met surging demands for injectable packaging in…
APAC Drawing on the findings of a recent report launched under the Business Ethics for APEC SMEs Initiative, Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) outlines the benefits for small and medium-sized enterprises (SMEs) of adopting ethical practices. Cueni highlights some of the key trends that emerged from report, conducted…
Global As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better understand their needs. However, as the below insights from four of Novartis Oncology’s patient engagement leads show, successfully integrating patient…
Asia-Pacific To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC has identified six key trends for emerging biotechs to watch. For a full interview with Senthil Sockalingam, head of IQVIA…
Australia Australia’s international outlook, strong science base, multi-ethnic English-speaking population and high educational and regulatory standards make it an attractive location to undertake clinical trials for medicines and vaccines. These fundamentals were foregrounded during the COVID-19 pandemic, when Australia was able to pivot quickly and develop capabilities in technology and tele-monitoring…
Australia In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already making to the global innovative pharmaceutical industry and why his country remains a particularly attractive clinical trials hub. “We…
Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…
Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…
Japan Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise real-world data (RWD) and real-world evidence (RWE) in its regulatory decision-making processes and how this will evolve moving forward. …
Denmark Copenhagen Capacity is Greater Copenhagen’s official organization for investment, promotion, and business development. Its CEO/managing director, Asbjørn Overgaard, outlines the fundamentals attracting life sciences firms to the region, stakeholders’ key investment concerns, and the work still to be done on closer alignment with neighbouring Sweden. Our goals are threefold:…
See our Cookie Privacy Policy Here